Pharm2Farm reported on Thursday the availability of the Pro-Larva mask that integrates the unique British technology based on copper nanoparticles to create an effective virucidal barrier against Covid-19 and other types of viruses, including the flu virus.
The company added that the Pro-Larva mask is the new antiviral mask that kills 99.9% of Covid-19 in the first five minutes of contact. The new revolutionary device, unlike the traditional masks, offers an unsurpassed level of protection against viruses, not only for those around the wearer but also for the wearer.
According to the company, the Pro-Larva mask is designed for hospitals, retirement homes, schools, retail and leisure sectors.
A spin out from Nottingham Trent University, Pharm2Farm Ltd produces and sells these masks through an exclusive license from NTU.
Tempus and Medtronic report positive ALERT trial results for AI-driven cardiac care
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Edwards Lifesciences reports positive two-year data for EVOQUE valve system
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Laronix and Greater Baltimore Medical Center launch Laronix MIRA Voice investigational study
BD receives CE Mark for Revello vascular covered stent
GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
BD receives FDA clearance for Surgiphor 1000mL irrigation system
Galderma secures EU, US and Canada approval for new Restylane syringe
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Advita Ortho updates Chime clinical exchange application
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems